Class II major histocompatibility complex transactivator (CIITA)

Class II major histocompatibility complex transactivator (CIITA) is a non-DNA-binding transcriptional coactivator that is essential for the expression of MHC class II genes and a critical regulator of immune system competency. CIITA coordinates chromatin remodeling and assembly of the enhanceosome at class II promoter sites through interactions with DNA-binding transcription factors (RFX, CREB, NF-Y) and the transcriptional machinery, acting as a "master control factor" for antigen presentation. Loss-of-function mutations cause severe immunodeficiency, while chromosomal rearrangements involving CIITA contribute to the development of certain lymphomas. CIITA’s activity is tightly regulated, notably being induced by interferon-gamma and restricted to immune cell types, reflecting its pivotal role in immune response and immune cell differentiation. To date, there are no direct pharmacological modulators of CIITA in clinical use, but its genetic and immunological roles make it a major target for research in immunodeficiency, cancer immunology, and transplant biology[1][2][3][4].

Other names

MHC class II transactivatorC2TAMHC2TANLRA (NLR family, acid domain containing)CIITAIVnucleotide-binding oligomerization domain, leucine rich repeat and acid domain containing[4][3]

Drugs or gene therapies restoring function may rescue MHC class II expression in deficiency states (experimental); no approved direct CIITA-targeted mechanism in clinical use. Therapies affecting IFN-gamma signaling may indirectly upregulate CIITA and thus MHC II expression[3][4].